Halozyme Therapeutics, Inc. HALO
Key Stats
- Today's Range
- $81.50 – $83.27
- 50-Day Range
- $65.59 – $84.44
- 52-Week Range
- $51.06 – $84.44
- Volume
- 1.57 million shs
- Average Volume
- 1.90 million shs
- Market Cap
- $9.79 billion
- P/E Ratio
- 28.86
- Dividend Yield
- —
Valuation
- P/E Ratio
- 28.86
- Price / Book
- 44.58
- Price / Sales
- 6.49
Short Interest
- Short Interest
- 9.37%
- Days to Cover
- 14.31
Financials (TTM)
- Revenue
- $1.51 billion
- Net Income
- $348.84 million
- Net Margin
- 23.13%
- Return on Equity
- 158.83%
- Debt-to-Equity
- —
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.